The Maharashtra Food and Drug Administration (FDA) has initiated significant action against prominent Bollywood actors Shah Rukh Khan, Ajay Devgn, and Tiger Shroff, issuing show cause notices regarding their involvement in an advertisement for Vimal Elaichi. The regulatory body alleges that the commercial constitutes surrogate advertising for Vimal Pan Masala, a product explicitly prohibited for sale and promotion within the state of Maharashtra.

These notices, dispatched earlier this week, demand a written explanation from each actor within 15 days. The FDA seeks clarification on their roles in the advertisement, asserting that the campaign creates an undeniable association with the Vimal Pan Masala brand, thereby potentially promoting a banned substance indirectly under the provisions of the Food Safety and Standards Act, 2006.

The Regulatory Scrutiny

The FDA’s examination of the Vimal Elaichi advertisement revealed a prima facie case of indirect promotion. The regulator highlighted that the Vimal brand is predominantly linked with pan masala, a product whose manufacture, storage, transportation, distribution, and sale have been prohibited in Maharashtra since July 13, 2026, under Section 30(2)(a) of the FSS Act, 2006. This move signifies a heightened focus by the Maharashtra FDA on curbing the subtle promotion of restricted products.

This particular action marks a new frontier for the FDA, as it is the first instance where the agency is actively scrutinizing surrogate advertising practices. The advertisement’s overall presentation, dialogue, product naming, and its established market context collectively raised “serious questions” for the regulator regarding its potential to indirectly promote a tobacco-related product, despite the ostensible promotion of a cardamom-based product.

Maharashtra’s Stance on Tobacco Products

Maharashtra has maintained a stringent stance against gutkha and pan masala containing tobacco or nicotine for over a decade, with the prohibition initially implemented in 2012. Under the leadership of Commissioner Tukaram Mundhe, the Maharashtra FDA has intensified its enforcement efforts, demonstrating a firm commitment to public health by cracking down on both the sale and promotion of these banned substances.

The state’s regulatory bodies have not shied away from employing robust legal frameworks. Beyond the FSS Act, the FDA has collaborated with police to invoke the Maharashtra Control of Organised Crime Act (MCOCA) in cases involving organized networks engaged in the illicit trade of gutkha, tobacco, or nicotine-containing pan masala, and similar prohibited items. This aggressive approach underscores the state’s determination to dismantle the supply chains of such products.

The Broader Advertising Landscape and Celebrity Endorsements

The issue of surrogate advertising is not new to India’s regulatory landscape, particularly concerning products like alcohol and tobacco, which face strict advertising restrictions. Brands often resort to promoting related, non-prohibited products (like soda, music CDs, or in this case, elaichi) under the same brand name to maintain visibility and recall for their restricted offerings. This practice has long been a grey area, challenging regulators to distinguish genuine product promotion from indirect brand building for banned items.

Celebrity endorsements, a powerful tool in India’s consumer market, add another layer of complexity. Bollywood stars, with their immense reach and influence, are often seen as credible faces for various brands. However, this power also comes with a significant responsibility. Public figures are increasingly expected to exercise due diligence regarding the products they endorse, especially when those products or their associated brands might skirt public health regulations.

The FDA’s current action highlights the evolving expectations from brand endorsers. The regulator has specifically demanded full copies of endorsement contracts, campaign briefs, remuneration details, and proof of due diligence from the actors. This indicates a move towards holding celebrities more accountable for the messages they convey, pushing them beyond merely being paid faces to becoming more responsible stakeholders in the advertising ecosystem.

Implications for Endorsers and Industry Standards

The invocation of Section 24 of the Food Safety and Standards Act, 2006, which addresses misleading and deceptive food advertisements, is crucial here. Furthermore, Section 53, which stipulates a penalty of up to Rs 10 lakh for anyone “party to the publication” of a misleading food advertisement, directly implicates the actors. This legal framework empowers the FDA to impose substantial fines, potentially setting a precedent for future celebrity endorsements.

This development could prompt a re-evaluation of endorsement contracts and due diligence processes across the entertainment industry. Actors and their management teams may need to conduct more thorough background checks on brands, particularly those with a history of association with restricted products. The incident serves as a stark reminder that the glamour of celebrity endorsements carries legal and ethical obligations that extend beyond the screen.

Editorial Context

This action by the Maharashtra FDA transcends a mere regulatory slap on the wrist; it signals a significant shift in how authorities intend to tackle surrogate advertising and celebrity accountability in India. For years, the practice of promoting ‘elaichi’ or ‘soda’ under a brand primarily known for pan masala or alcohol has been an open secret, exploiting loopholes in advertising laws. By directly challenging Bollywood’s biggest names, the FDA is sending an unequivocal message that such practices will no longer be tolerated, irrespective of the star power involved.

In the long term, this could redefine the ethical boundaries of advertising in India, particularly for products with public health implications. It places a greater onus on celebrities to scrutinize their endorsements, potentially leading to a more responsible advertising ecosystem. Furthermore, it empowers consumer advocacy groups and strengthens the regulatory framework, ensuring that public health concerns take precedence over commercial interests, thereby fostering a healthier consumption culture in the state and potentially inspiring similar actions nationwide.